Moreover, Schafer et al. reported that beneficial effects of PDE5 inhibition was dependent on whether the RV remodeling was achieved through monocrotaline-induced pulmonary hypertension or PA banding, with the latter not benefiting from the inhibition of PDE5 [14]. Here, PDE5A is linked to pulmonary arterial hypertension.